Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells

Journal of Biological Chemistry

Volumn 288, Issue 11, 2013, Pages 7467-7480

  Gourlaouen, Morgane ^a   Welti, Jonathan C ^a   Vasudev, Naveen S ^a   Reynolds, Andrew R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXTRACELLULAR; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; HEPATOCYTE GROWTH FACTOR; RECEPTOR TRAFFICKING; SMALL MOLECULE INHIBITOR; TUMOR ANGIOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

CELL CULTURE; ENDOTHELIAL CELLS; ENZYMES; MOLECULES;

MOLECULAR BIOLOGY;

CLATHRIN; DYNAMIN II; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RAF PROTEIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; INTRACELLULAR TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; CELL LINE, TUMOR; ENDOCYTOSIS; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84875157022     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.446401     Document Type: Article

References (64)

1. Ferrara, N., and Kerbel, R. S. (2005) Angiogenesis as a therapeutic target. Nature 438, 967-974
2. Hanahan, D., and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364
3. Carmeliet, P., De Smet, F., Loges, S., and Mazzone, M. (2009) Branching morphogenesis and antiangiogenesis candidates. Tip cells lead the way. Nat. Rev. Clin. Oncol. 6, 315-326
4. Olsson, A. K., Dimberg, A., Kreuger, J., and Claesson-Welsh, L. (2006) VEGF receptor signaling. In control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371
5. Ferrara, N., Gerber, H. P., and LeCouter, J. (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676
6. Koch, S., Tugues, S., Li, X., Gualandi, L., and Claesson-Welsh, L. (2011) Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 437, 169-183
7. Kerbel, R. S. (2008) Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049
8. Ferrara, N., Hillan, K. J., Gerber, H. P., and Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400
9. Ellis, L. M., and Hicklin, D. J. (2008) VEGF-targeted therapy. Mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591
10. Bergers, G., and Hanahan, D. (2008) Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603
11. Azam, F., Mehta, S., and Harris, A. L. (2010) Mechanisms of resistance to antiangiogenesis therapy. Eur. J. Cancer 46, 1323-1332
12. Rini, B. I., and Atkins, M. B. (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 10, 992-1000
13. Bottsford-Miller, J. N., Coleman, R. L., and Sood, A. K. (2012) Resistance and escape from antiangiogenesis therapy. Clinical implications and future strategies. J. Clin. Oncol. 30, 4026-4034
14. Sennino, B., and McDonald, D. M. (2012) Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 12, 699-709
15. Kerbel, R. S. (2005) Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8, 269-271
16. Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., and Rusnati, M. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16, 159-178
17. Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., and Comoglio, P. M. (1992) Hepatocyte growth factor is a potent angiogenic factor that stimulates endothelial cell motility and growth. J. Cell Biol. 119, 629-641
18. Silvagno, F., Follenzi, A., Arese, M., Prat, M., Giraudo, E., Gaudino, G., Camussi, G., Comoglio, P. M., and Bussolino, F. (1995) In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler. Thromb. Vasc. Biol. 15, 1857-1865
19. Welti, J. C., Gourlaouen, M., Powles, T., Kudahetti, S. C., Wilson, P., Berney, D. M., and Reynolds, A. R. (2011) Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30, 1183-1193
20. Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., and Christensen, J. G. (2010) HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 70, 10090-10100
21. Casanovas, O., Hicklin, D. J., Bergers, G., and Hanahan, D. (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309
22. Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W. T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P. J., Zhu, M., Ancukiewicz, M., Mrugala, M. M., Plotkin, S., Drappatz, J., Louis, D. N., Ivy, P., Scadden, D. T., Benner, T., Loeffler, J. S., Wen, P. Y., and Jain, R. K. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95
23. Porta, C., Paglino, C., Imarisio, I., Ganini, C., Sacchi, L., Quaglini, S., Giunta, V., and De Amici, M. (2013) Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 84, 115-122
24. Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., Lieu, C., Yan, S., Tran, H. T., Ellis, L. M., Abbruzzese, J. L., and Heymach, J. V. (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer. Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 28, 453-459
25. Cross, M. J., and Claesson-Welsh, L. (2001) FGF and VEGF function in angiogenesis. Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22, 201-207
26. Alavi, A., Hood, J. D., Frausto, R., Stupack, D. G., and Cheresh, D. A. (2003) Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301, 94-96
27. Eliceiri, B. P., Klemke, R., Strömblad, S., and Cheresh, D. A. (1998) Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol. 140, 1255-1263
28. Mavria, G., Vercoulen, Y., Yeo, M., Paterson, H., Karasarides, M., Marais, R., Bird, D., and Marshall, C. J. (2006) ERK-MAPK signaling opposes Rho kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9, 33-44
29. Wei, G., Srinivasan, R., Cantemir-Stone, C. Z., Sharma, S. M., Santhanam, R., Weinstein, M., Muthusamy, N., Man, A. K., Oshima, R. G., Leone, G., and Ostrowski, M. C. (2009) Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood 114, 1123-1130
30. Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., and Cheresh, D. A. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407
31. Reynolds, A. R., Moein Moghimi, S., and Hodivala-Dilke, K. (2003) Nanoparticle- mediated gene delivery to tumour neovasculature. Trends Mol. Med. 9, 2-4
32. Ewan, L. C., Jopling, H. M., Jia, H., Mittar, S., Bagherzadeh, A., Howell, G. J., Walker, J. H., Zachary, I. C., and Ponnambalam, S. (2006) Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting, and degradation in endothelial cells. Traffic 7, 1270-1282
33. Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C., and Dejana, E. (2006) Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174, 593-604
34. Damke, H., Baba, T., Warnock, D. E., and Schmid, S. L. (1994) Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J. Cell Biol. 127, 915-934
35. Sorkin, A., and von Zastrow, M. (2009) Endocytosis and signaling. Intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 10, 609-622
36. Scott, A., and Mellor, H. (2009) VEGF receptor trafficking in angiogenesis. Biochem. Soc. Trans 37, 1184-1188
37. Eichmann, A., and Simons, M. (2012) VEGF signaling inside vascular endothelial cells and beyond. Curr. Opin. Cell Biol. 24, 188-193
38. Duval, M., Bédard-Goulet, S., Delisle, C., and Gratton, J. P. (2003) Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells. J. Biol. Chem. 278, 20091-20097
39. Murdaca, J., Treins, C., Monthouël-Kartmann, M. N., Pontier-Bres, R., Kumar, S., Van Obberghen, E., and Giorgetti-Peraldi, S. (2004) Grb10 prevents Nedd4-mediated vascular endothelial growth factor receptor-2 degradation. J. Biol. Chem. 279, 26754-26761
40. Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., and Acker-Palmer, A. (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487-491
41. Lanahan, A. A., Hermans, K., Claes, F., Kerley-Hamilton, J. S., Zhuang, Z. W., Giordano, F. J., Carmeliet, P., and Simons, M. (2010) VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev. Cell 18, 713-724
42. Reynolds, A. R., Hart, I. R., Watson, A. R., Welti, J. C., Silva, R. G., Robinson, S. D., Da Violante, G., Gourlaouen, M., Salih, M., Jones, M. C., Jones, D. T., Saunders, G., Kostourou, V., Perron-Sierra, F., Norman, J. C., Tucker, G. C., and Hodivala-Dilke, K. M. (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15, 392-400
43. Nakatsu, M. N., and Hughes, C. C. (2008) An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol. 443, 65-82
44. Mahadevan, V., Hart, I. R., and Lewis, G. P. (1989) Factors influencing blood supply in wound granuloma quantitated by a new in vivo technique. Cancer Res. 49, 415-419
45. da Silva, R. G., Tavora, B., Robinson, S. D., Reynolds, L. E., Szekeres, C., Lamar, J., Batista, S., Kostourou, V., Germain, M. A., Reynolds, A. R., Jones, D. T., Watson, A. R., Jones, J. L., Harris, A., Hart, I. R., Iruela-Arispe, M. L., Dipersio, C. M., Kreidberg, J. A., and Hodivala-Dilke, K. M. (2010) Endothelial α3β1-integrin represses pathological angiogenesis and sustains endothelial- VEGF. Am. J. Pathol. 177, 1534-1548
46. von Kleist, L., Stahlschmidt, W., Bulut, H., Gromova, K., Puchkov, D., Robertson, M. J., MacGregor, K. A., Tomilin, N., Tomlin, N., Pechstein, A., Chau, N., Chircop, M., Sakoff, J., von Kries, J. P., Saenger, W., Kräusslich, H. G., Shupliakov, O., Robinson, P. J., McCluskey, A., and Haucke, V. (2011) Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell 146, 471-484
47. Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C., and Kirchhausen, T. (2006) Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839-850
48. Wang, Y., Nakayama, M., Pitulescu, M. E., Schmidt, T. S., Bochenek, M. L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Lüthi, U., Barberis, A., Benjamin, L. E., Mäkinen, T., Nobes, C. D., and Adams, R. H. (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483-486
49. Takahashi, T., Yamaguchi, S., Chida, K., and Shibuya, M. (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768-2778
50. Kolch, W. (2000) Meaningful relationships. The regulation of the Ras/Raf/ MEK/ERK pathway by protein interactions. Biochem. J. 351, 289-305
51. Kermorgant, S., and Parker, P. J. (2005) c-Met signaling. Spatiotemporal decisions. Cell Cycle 4, 352-355
52. Wesche, J., Haglund, K., and Haugsten, E. M. (2011) Fibroblast growth factors and their receptors in cancer. Biochem. J. 437, 199-213
53. Miaczynska, M., Pelkmans, L., and Zerial, M. (2004) Not just a sink. Endosomes in control of signal transduction. Curr. Opin. Cell Biol. 16, 400-406
54. Jakobsson, L., Kreuger, J., Holmborn, K., Lundin, L., Eriksson, I., Kjellén, L., and Claesson-Welsh, L. (2006) Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev. Cell 10, 625-634
55. Anderson, S. M., Shergill, B., Barry, Z. T., Manousiouthakis, E., Chen, T. T., Botvinick, E., Platt, M. O., Iruela-Arispe, M. L., and Segura, T. (2011) VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF. Integr Biol. (Camb) 3, 887-896
56. Daaka, Y., Luttrell, L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. S., Caron, M. G., and Lefkowitz, R. J. (1998) Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J. Biol. Chem. 273, 685-688
57. Teis, D., Wunderlich, W., and Huber, L. A. (2002) Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev. Cell 3, 803-814
58. Sousa, L. P., Lax, I., Shen, H., Ferguson, S. M., De Camilli, P., and Schlessinger, J. (2012) Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane. Proc. Natl. Acad. Sci. U.S.A. 109, 4419-4424
59. Luwor, R. B., Chin, X., McGeachie, A. B., Robinson, P. J., and Zhu, H. J. (2012) Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation. Growth Factors 30, 220-229
60. Goh, L. K., Huang, F., Kim, W., Gygi, S., and Sorkin, A. (2010) Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J. Cell Biol. 189, 871-883
61. Ballmer-Hofer, K., Andersson, A. E., Ratcliffe, L. E., and Berger, P. (2011) Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 118, 816-826
62. Sarker, D., Molife, R., Evans, T. R., Hardie, M., Marriott, C., Butzberger- Zimmerli, P., Morrison, R., Fox, J. A., Heise, C., Louie, S., Aziz, N., Garzon, F., Michelson, G., Judson, I. R., Jadayel, D., Braendle, E., and de Bono, J. S. (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 14, 2075-2081
63. Jonker, D. J., Rosen, L. S., Sawyer, M. B., de Braud, F., Wilding, G., Sweeney, C. J., Jayson, G. C., McArthur, G. A., Rustin, G., Goss, G., Kantor, J., Velasquez, L., Syed, S., Mokliatchouk, O., Feltquate, D. M., Kollia, G., Nuyten, D. S., and Galbraith, S. (2011) A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann. Oncol. 22, 1413-1419
64. Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E., Janisch, L., Nauling, F., Hong, D. S., Ng, C. S., Ye, L., Gagel, R. F., Frye, J., Müller, T., Ratain, M. J., and Salgia, R. (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29, 2660-2666